LINE-1 hypomethylation level in patients with soft tissue tumor.
Keywords:
LINE-1, methylation, peripheral blood leukocytes, soft tissue tumorAbstract
Background : LINE-1 is a non-long terminal retrotransposon, comprising 17% in human genome. The aberrant methylation of LINE-1 can cause mitotic recombination and genomic instability leading to soft tissue tumor. However, the study of LINE-1 methylation in soft tissue tumor has received little attention.
Objectives : To determine LINE-1 methylation level in neoplastic tissues compared with non-neoplastic adjacent tissues of soft tissue tumor patients and to investigate the correlation of LINE-1 methylation between neoplastic tissues and peripheral blood leukocytes.
Methods : Thirty-five patients with soft tissue tumor and 107 healthy controls were recruited. LINE-1 methylation level was analyzed by using quantitative combined bisulfite restriction analysis.
Results : LINE-1 methylation level was statistically significantly lower (P = 0.036) in neoplastic tissues than in non-neoplastic adjacent tissues but there was no significant difference in LINE-1 methylation among benign tumor, malignant tumor, and non-neoplastic adjacent tissues. In addition, LINE-1 methylation was not different in each subgroup of soft tissue tumor. Nevertheless, there was a positive correlation of LINE-1 methylation level between neoplastic tissues and peripheral blood leukocytes (r = 0.812, P < 0.001).
Conclusion : These findings suggest that there was LINE-1 hypomethylation in soft tissue tumor. Thus, LINE-1 hypomethylation might play a crucial role in the pathogenesis of soft tissue tumor.
Downloads
References
รังสีรักษาและมะเร็งวิทยา ฝ่ายรังสีวิทยา โรงพยาบาลจุฬาลงกรณ์ (ChulaCancer). โรคมะเร็งเนื้อเยื่ออ่อน [อินเทอร์เน็ต]. 2560 [20 ก.พ. 2560]. เข้าถึงได้จาก : http://www.chulacancer.net.
National Cancer Institute. Hospital based-cancer registry annual report 2012.Bangkok: National Cancer Institute Department of Medical Services Ministry of Public Health; 2012.p. 34-60.
Kirkpatrick CJ, Alves A, Kohler H, Kriegsmann J, Bittinger F, Otto M, et al. Biomaterial-induced sarcoma: A novel model to study preneoplastic change. Am J Pathol 2000; 156:1455-67.
https://doi.org/10.1016/S0002-9440(10)65014-6
Ofluoglu O, Boriani S, Gasbarrini A, De Iure F, Donthineni R. Diagnosis and planning in the management of musculoskeletal tumors: surgical perspective. Semin Intervent Radiol 2010;27:185-90.
https://doi.org/10.1055/s-0030-1253516
Kazazian HH Jr, Moran JV. The impact of L1 retrotransposons on the human genome. Nat Genet 1998;19:19-24. https://doi.org/10.1038/ng0598-19
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. https://doi.org/10.1038/35057062
Brouha B, Meischl C, Ostertag E, de Boer M, Zhang Y, Neijens H, et al. Evidence consistent with human L1 retrotransposition in maternal meiosis I. Am J Hum Genet 2002;71:327-36.
https://doi.org/10.1086/341722
van den Hurk JA, Meij IC, Seleme MC, Kano H, Nikopoulos K, Hoefsloot LH, et al. L1 retrotransposition can occur early in human embryonic development. Hum Mol Genet 2007;16:1587-92.
https://doi.org/10.1093/hmg/ddm108
Kaer K, Speek M. Retroelements in human disease. Gene 2013;518:231-41.
https://doi.org/10.1016/j.gene.2013.01.008
Chen JM, Stenson PD, Cooper DN, Ferec C. A systematic analysis of LINE-1 endonucleasedependent retrotranspositional events causing human genetic disease. Hum Genet 2005;117:411-27.
https://doi.org/10.1007/s00439-005-1321-0
Xiao-Jie L, Hui-Ying X, Qi X, Jiang X, Shi-Jie M. LINE-1 in cancer: multifaceted functions and potential clinical implications. Genet Med 2016;18:431-9. https://doi.org/10.1038/gim.2015.119
Egger G, Liang G, AparicioA, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63. https://doi.org/10.1038/nature02625
Soozangar N, Sadeghi MR, Jeddi F, Somi MH, Shirmohamadi M, Samadi N. Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer. J Cell Physiol 2017 Sep 9. doi:10.1002/jcp.26176. https://doi.org/10.1002/jcp.26176
Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011;3:75ra25.
https://doi.org/10.1126/scitranslmed.3001875
Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006; 66:10621-9. https://doi.org/10.1158/0008-5472.CAN-06-1687
Samowitz WS. The CpG island methylator phenotype in colorectal cancer. J Mol Diagn 2007;9:281-3.
https://doi.org/10.2353/jmoldx.2007.070031
Jeong S, Lee K, Wen X, Kim Y, Cho NY, Jang JJ, et al. Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma. BMCCancer 2017;17:588.
https://doi.org/10.1186/s12885-017-3595-8
Kitkumthorn N, Mutirangura A. LINE-1 methylation difference between ameloblastoma and keratocystic odontogenic tumor. Oral Dis 2010;16:286-91.
https://doi.org/10.1111/j.1601-0825.2009.01640.x
Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009;30:1330-5.
https://doi.org/10.1093/carcin/bgp149
Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis 2004;19:95-101.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chulalongkorn Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
